Centiva Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Centiva Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,705	Closed	-$1.15M	–	2191
2025 Q1	$1.15M	Buy	+8,705	New	+$1.08M	0.03%	410
2023 Q2	–	Sell	-3,735	Closed	-$202K	–	2079
2023 Q1	$202K	Buy	+3,735	New	+$181K	0.01%	1237
2021 Q4	–	Sell	-5,561	Closed	-$207K	–	1599
2021 Q3	$207K	Buy	+5,561	New	+$193K	0.01%	915

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Centiva Capital's ITCI Position: Q2 2025 in Review

Centiva Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 8,705 shares — an estimated $1.15M sold.

Centiva Capital first reported a position in ITCI in Q3 2021 and held it in 3 quarters. The position peaked at $1.15M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Centiva Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Centiva Capital sold 8,705 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.15M.
Centiva Capital first reported a position in Intra-Cellular Therapies Inc. in Q3 2021 and held it in 3 quarters.
Centiva Capital's Intra-Cellular Therapies Inc. position peaked at $1.15M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.